New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics

June 2016

Welcome to the June 2016 issue of PharmSource PERISCOPE

This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.

Enjoy the June issue!

The PharmSource Team

 

PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity

Lead Type May 2016 CY 2016
Early Development 130 474
Late Development 114 500
Biologic 101 422
Small Molecule 256 1082
Parenteral 110 497
Oral 102 416
New Financings 81 398
Total Drug Leads 394 1771
Total Device &
Diagnostic Leads
171 720

*Total leads include acquisitions/alliances, company acquisition/alliances and events.


 

Pipeline Tip

DelMar Pharmaceuticals plans to initiate a Phase III trial with VAL-083 for the treatment of refractory glioblastoma multiforme:

  • Therapeutic Area: Oncology – Chemotherapy
  • Dosage Form: Parenteral
  • API: Chemical – Cytotoxic

Get deeper information about the likely upcoming needs of DelMar, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.
 

It’s Getting Harder for Bio/Pharma to Raise Money

by Jim Miller, President, PharmSource

It’s not surprising that CROs and CMOs may not be feeling the impact of the funding downturn quite yet. After the 2008 global financial crisis, it took two years for IND filings and Phase 1 clinical trial starts to reflect the funding decline.

Companies used their remaining cash to get candidates into the clinic as quickly as possible in hopes of demonstrating proof-of-concept, the prerequisite for licensing deals and more external funding. The most recent downturn in external financing is barely a year old, so it could be a while before CROs and CMOs really feel the pinch.

This is a good time for service providers to focus on resurrecting their business development skills. After several years of just answering unsolicited external inquiries, they will soon have to… read on
 

European Clinical Pipeline Activity

by Saul Richmond, Director, Market Intelligence

Until the recent downturn in external financing for early stage biopharma companies, the past couple of years had witnessed something of a renaissance in biopharma funding, led as usual, by the United States. The positive mood had spread beyond the US, and this was reflected in a significant increase in pipeline activity emanating from companies with European operations.

In 2015, the PharmSource Lead Sheet identified at least 480 drugs in European companies that were actively progressing through clinical trials, of which 242 (approximately 50%) were early stage (Discovery, Preclinical or Phase I). Approximately one in six of these reported positive results, and almost 20% of companies planned to initiate or… read on
 

Follow the Money to

Medical Device & Diagnostic Opportunities

Spotlight on EndoStim, Inc.

EndoStim is a private US company that develops neurostimulation devices for the treatment of neuromuscular disorders. They raised $25 million in a completion of a venture capital investment

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support a US pivotal clinical trial and global commercialization efforts for its… read on
 
 

Follow the Money to

Pharmaceutical Opportunities

Spotlight on Ignyta, Inc.

Ignyta is a U.S. public biopharmaceutical company that develops personalized medicine tests to improve the diagnosis and treatment of patients with autoimmune diseases such as rheumatoid arthritis and lupus. They plan to raise $50 million in a completion of a secondary public offering.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to complete development activities related to its companion diagnostics for targeted therapeutics and to support R&D activities for its pipeline, including… read on
 

PharmSource Lead Sheet

The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.

Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.

See for yourself how this resource can be a vital tool for building your brand and growing your market share.

To request a test-drive today, contact Nathaniel Celentano at nathaniel@pharmsouce.com / 1-703-383-4903, ext. 112 (ET USA).